WHO Grants EUL to Covavaxin in India

November 4, 2021

Yesterday, the WHO granted emergency use listing (EUL) to Covavaxin, the first COVID-19 vaccine developed in India. The WHO stated that the vaccine met standards for protection at 78% efficacy against COVID-19 at any severity, and that “the benefits of the vaccine far outweigh risks.” The vaccine can be used worldwide for adults 18+ using a two-dose method.

Covavaxin was approved for use in India by the government in January and applied for EUL in April. Approximately 50 million doses are currently being manufactured each month.

Other WHO authorized vaccines include AstraZeneca (and their partner, Serum Institute of India, which uses a version of AstraZeneca’s vaccine called Covishield), Pfizer-BioNTech, Moderna, Johnson & Jonson, as well as Sinovac and Sinopharm. Learn more about these WHO authorized vaccines, including highlights of their research and development, here.





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.